These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20947351)

  • 1. Inhibitors selective for HDAC6 in enzymes and cells.
    Gupta PK; Reid RC; Liu L; Lucke AJ; Broomfield SA; Andrews MR; Sweet MJ; Fairlie DP
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7067-70. PubMed ID: 20947351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
    Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM
    J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market.
    Körner M; Tibes U
    Prog Med Chem; 2008; 46():205-80. PubMed ID: 18381127
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
    Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
    ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
    Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages.
    Han SB; Lee JK
    Arch Pharm Res; 2009 Apr; 32(4):613-24. PubMed ID: 19407980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
    Suzuki T; Kouketsu A; Itoh Y; Hisakawa S; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2006 Aug; 49(16):4809-12. PubMed ID: 16884291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
    Wong JC; Hong R; Schreiber SL
    J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
    Giannini G; Marzi M; Pezzi R; Brunetti T; Battistuzzi G; Marzo MD; Cabri W; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2346-9. PubMed ID: 19285395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
    Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.
    Hildmann C; Wegener D; Riester D; Hempel R; Schober A; Merana J; Giurato L; Guccione S; Nielsen TK; Ficner R; Schwienhorst A
    J Biotechnol; 2006 Jun; 124(1):258-70. PubMed ID: 16567013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
    Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.